Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 6/2010

01-08-2010 | Research Paper

Proteomic strategies and challenges in tumor metastasis research

Authors: Petra Hudler, Masa Gorsic, Radovan Komel

Published in: Clinical & Experimental Metastasis | Issue 6/2010

Login to get access

Abstract

The rapidly evolving field of proteomics offers new approaches to understanding the pathogenesis of cancer and metastatic disease. Although numerous tumor markers have been identified with different genomic methods in the past, most are either not specific or sensitive enough to be used in routine clinical setting. The rationale for proteomic profiling is based on the fact that proteins represent the dynamic state of the cells, reflecting pathophysiological changes in the disease more accurately than genomic and epigenetic alterations. Emerging proteomic techniques allow simultaneous assessment of a large number of proteins at one time. The study of protein profiles in complex systems, such as plasma, serum or tissues of cancer patients is likely to become valuable for monitoring the response of patients during treatment or for detecting recurrence of the disease.
Literature
1.
Fokas E et al (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26(3–4):705–715CrossRefPubMed
2.
Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340CrossRefPubMed
3.
4.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458CrossRefPubMed
5.
Langley RR, Fidler IJ (2007) Tumor cell–organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28(3):297–321CrossRefPubMed
6.
Chen YR et al (2006) Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 5(10):2727–2742CrossRefPubMed
7.
Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845–856CrossRefPubMed
8.
Polanski M, Anderson NL (2006) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2:1–48
9.
10.
11.
Zieglschmid V, Hollmann C, Bocher O (2005) Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 42(2):155–196CrossRefPubMed
12.
Kumar S, Mohan A, Guleria R (2006) Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 11(5):385–405CrossRefPubMed
13.
Alaiya A, Al-Mohanna M, Linder S (2005) Clinical cancer proteomics: promises and pitfalls. J Proteome Res 4(4):1213–1222CrossRefPubMed
14.
Cho WC, Cheng CH (2007) Oncoproteomics: current trends and future perspectives. Expert Rev Proteomics 4(3):401–410CrossRefPubMed
15.
Ciordia S, de Los Rios V, Albar JP (2006) Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 8(8):566–580CrossRefPubMed
16.
Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452(7187):571–579CrossRefPubMed
17.
Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715CrossRefPubMed
18.
Pankova K et al (2010) The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci 67(1):63–71CrossRefPubMed
19.
Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12(8):895–904CrossRefPubMed
20.
Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204CrossRefPubMed
21.
Steiniger SC et al (2008) Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 26(12):3037–3046CrossRefPubMed
22.
Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324(5935):1670–1673CrossRefPubMed
23.
Sullivan JP, Minna JD, Shay JW (2010) Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev 29(1):61–72CrossRefPubMed
24.
Lu J et al (2010) Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126(3):669–683CrossRefPubMed
25.
Faca V, Krasnoselsky A, Hanash S (2007) Innovative proteomic approaches for cancer biomarker discovery. Biotechniques 43(3):279, 281–283, 285
26.
Petricoin E et al (2004) Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 3(2):209–217CrossRefPubMed
27.
Pepe MS et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061CrossRefPubMed
28.
National Comprehensive Cancer Network I (2007) NCCN clinical practice guidelines in oncology: prostate cancer v.1.2007
29.
30.
Lu M et al (2007) Proteomics and mass spectrometry for cancer biomarker discovery. Biomark Insights 2:347–360PubMed
31.
Mischak H et al (2009) Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 28(5):703–724CrossRefPubMed
32.
Van Eyk JE, Dunn MJ (2008) Clinical proteomics: from diagnosis to therapy. Wiley-VCH, Weinheim
33.
Liotta LA, Petricoin EF (2006) Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 116(1):26–30CrossRefPubMed
34.
Omenn GS et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5(13):3226–3245CrossRefPubMed
35.
de la Grange P et al (2010) Splicing factor and exon profiling across human tissues. Nucleic Acids Res 38(9):2825–2838CrossRefPubMed
36.
Dutertre M et al (2010) Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70(3):896–905CrossRefPubMed
37.
38.
Warder SE et al (2009) Reducing agent-mediated precipitation of high-abundance plasma proteins. Anal Biochem 387(2):184–193CrossRefPubMed
39.
Fang X, Zhang WW (2008) Affinity separation and enrichment methods in proteomic analysis. J Proteomics 71(3):284–303CrossRefPubMed
40.
Polaskova V et al (2010) High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 31(3):471–482CrossRefPubMed
41.
Luchini A et al (2010) Nanoparticle technology: addressing the fundamental roadblocks to protein biomarker discovery. Curr Mol Med 10(2):133–141CrossRefPubMed
42.
Hortin GL (2006) The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 52(7):1223–1237CrossRefPubMed
43.
Lai X et al (2009) A proteomic workflow for discovery of serum carrier protein-bound biomarker candidates of alcohol abuse using LC-MS/MS. Electrophoresis 30(12):2207–2214CrossRefPubMed
44.
Lopez MF et al (2005) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51(10):1946–1954CrossRefPubMed
45.
Lowenthal MS et al (2005) Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51(10):1933–1945CrossRefPubMed
46.
Fredolini C et al (2009) Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. Drug Test Anal 1(9–10):447–454CrossRefPubMed
47.
Longo C et al (2009) Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One 4(3):e4763CrossRefPubMed
48.
Luchini A et al (2008) Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 8(1):350–361CrossRefPubMed
49.
Kolch W, Mischak H, Pitt AR (2005) The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 108(5):369–383CrossRefPubMed
50.
Everley PA, Zetter BR (2005) Proteomics in tumor progression and metastasis. Ann N Y Acad Sci 1059:1–10CrossRefPubMed
51.
52.
O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250(10):4007–4021PubMed
53.
Kleparnik K, Bocek P (2010) Electrophoresis today and tomorrow: helping biologists’ dreams come true. Bioessays 32(3):218–226CrossRefPubMed
54.
Gorg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12):3665–3685CrossRefPubMed
55.
Martin B et al (2008) Biological pathways contributing to organ-specific phenotype of brain metastatic cells. J Proteome Res 7(3):908–920CrossRefPubMed
56.
Hatakeyama H et al (2006) Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics 6(23):6300–6316CrossRefPubMed
57.
Han X, Aslanian A, Yates JR III (2008) Mass spectrometry for proteomics. Curr Opin Chem Biol 12(5):483–490CrossRefPubMed
58.
Pan S et al (2009) Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8(2):787–797CrossRefPubMed
59.
McAlister GC et al (2010) Analysis of tandem mass spectra by FTMS for improved large-scale proteomics with superior protein quantification. Anal Chem 82(1):316–322CrossRefPubMed
60.
Kicman AT, Parkin MC, Iles RK (2007) An introduction to mass spectrometry based proteomics-detection and characterization of gonadotropins and related molecules. Mol Cell Endocrinol 260–262:212–227CrossRefPubMed
61.
Wei J et al (2008) Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 28(1A):327–334PubMed
62.
Liao CC et al (2010) Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J Surg Oncol 8:33CrossRefPubMed
63.
Schwartz SA et al (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65(17):7674–7681PubMed
64.
Vydra J et al (2008) Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer 8:107CrossRefPubMed
65.
De Bock M et al (2010) Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010:906082PubMed
66.
Wang Q et al (2009) Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9:287CrossRefPubMed
67.
Smith FM et al (2007) Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 245(2):259–266CrossRefPubMed
68.
Qiu FM et al (2009) Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res 28:126CrossRefPubMed
69.
Asara JM et al (2008) A label-free quantification method by MS/MS TIC compared to SILAC and spectral counting in a proteomics screen. Proteomics 8(5):994–999CrossRefPubMed
70.
Faca VM et al (2008) Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 3(6):e2425CrossRefPubMed
71.
Zhang DY et al (2009) Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div 4:20CrossRefPubMed
72.
Bertone P, Snyder M (2005) Advances in functional protein microarray technology. FEBS J 272(21):5400–5411CrossRefPubMed
73.
Harmsen MM, De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77(1):13–22CrossRefPubMed
74.
Kastelic D et al (2009) A single-step procedure of recombinant library construction for the selection of efficiently produced llama VH binders directed against cancer markers. J Immunol Methods 350(1–2):54–62CrossRefPubMed
75.
76.
Osterfeld SJ et al (2008) Multiplex protein assays based on real-time magnetic nanotag sensing. Proc Natl Acad Sci USA 105(52):20637–20640CrossRefPubMed
77.
Fei YY et al (2008) A novel high-throughput scanning microscope for label-free detection of protein and small-molecule chemical microarrays. Rev Sci Instrum 79(1):013708CrossRefPubMed
78.
Grubb RL et al (2009) Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res 8(6):3044–3054CrossRefPubMed
79.
Tahara H et al (2009) Emerging concepts in biomarker discovery; the US–Japan workshop on immunological molecular markers in oncology. J Transl Med 7:45CrossRefPubMed
80.
Gulmann C et al (2009) Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol 218(4):514–519CrossRefPubMed
81.
Wulfkuhle JD et al (2008) Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 7(4):1508–1517CrossRefPubMed
82.
He M, Taussig MJ (2001) Single step generation of protein arrays from DNA by cell-free expression and in situ immobilisation (PISA method). Nucleic Acids Res 29(15):E73CrossRefPubMed
83.
He M, Taussig MJ (2008) Production of protein arrays by cell-free systems. Methods Mol Biol 484:207–215CrossRefPubMed
84.
Sanchez-Carbayo M (2010) Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens. Tumour Biol 31(2):103–112CrossRefPubMed
85.
Wulfkuhle JD et al (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3(11):2085–2090CrossRefPubMed
86.
Nettikadan S et al (2006) Detection and quantification of protein biomarkers from fewer than 10 cells. Mol Cell Proteomics 5(5):895–901CrossRefPubMed
87.
Song S et al (2007) A cancer protein microarray platform using antibody fragments and its clinical applications. Mol Biosyst 3(2):151–158CrossRefPubMed
88.
Palagi PM et al (2006) Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics 6(20):5435–5444CrossRefPubMed
89.
Blueggel M, Chamrad D, Meyer HE (2004) Bioinformatics in proteomics. Curr Pharm Biotechnol 5(1):79–88CrossRefPubMed
90.
Tan NC et al (2009) Application of multiple statistical tests to enhance mass spectrometry-based biomarker discovery. BMC Bioinformatics 10:144CrossRefPubMed
91.
Wang Y, Hanley R, Klemke RL (2006) Computational methods for comparison of large genomic and proteomic datasets reveal protein markers of metastatic cancer. J Proteome Res 5(4):907–915CrossRefPubMed
92.
Beretta L (2007) Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 4(10):785–786CrossRefPubMed
93.
Espina V et al (2008) A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 7(10):1998–2018CrossRefPubMed
Metadata
Title
Proteomic strategies and challenges in tumor metastasis research
Authors
Petra Hudler
Masa Gorsic
Radovan Komel
Publication date
01-08-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9339-7

Other articles of this Issue 6/2010

Clinical & Experimental Metastasis 6/2010 Go to the issue

Editorial Comment

Genomics of metastatic progression

Research Paper

Lung cancer progression and metastasis from the prognostic point of view

Research Paper

Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Research Paper

Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs

Research Paper

Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution

Review

Childhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits